Published in Antiviral Res on August 20, 2013
Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc. Mater Sci Eng C Mater Biol Appl (2016) 0.77
Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral release. J Control Release (2015) 0.75
Pharmacokinetics of the protein microbicide 5P12-RANTES in sheep following single dose vaginal gel administration. Antimicrob Agents Chemother (2017) 0.75
A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res (1995) 12.09
Sexual transmission of HIV. N Engl J Med (1997) 6.84
Elementary osmotic pump. J Pharm Sci (1975) 2.69
17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause (2000) 1.82
Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations. Ann Biomed Eng (1976) 1.50
Oral osmotically driven systems: 30 years of development and clinical use. Eur J Pharm Biopharm (2009) 1.20
Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev (2005) 1.19
Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract Res Clin Obstet Gynaecol (2012) 1.01
Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2. Antimicrob Agents Chemother (2007) 1.00
Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci (2007) 0.97
Osmotic micropumps for drug delivery. Adv Drug Deliv Rev (2012) 0.93
Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy. Int J Womens Health (2013) 0.90
Current methods of labor induction. Semin Perinatol (2012) 0.90
Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention. Antiviral Res (2012) 0.88
Effect of plasticizers on some physical properties of cellulose acetate phthalate films. J Pharm Sci (1971) 0.88
Permeability of cellulose polymers: water vapour transmission rates. J Pharm Pharmacol (1990) 0.84
Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. Int J Pharm (2011) 0.82
Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis (2007) 2.57
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One (2011) 2.00
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis (2009) 1.81
PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS (2007) 1.75
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother (2004) 1.69
Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat Immunol (2012) 1.65
Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol (2006) 1.64
Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci (2009) 1.58
Herpes simplex virus triggers activation of calcium-signaling pathways. J Cell Biol (2003) 1.58
Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol (2004) 1.58
Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology (2006) 1.58
PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis (2005) 1.54
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis (2007) 1.48
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One (2010) 1.46
Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients. Pediatr Transplant (2011) 1.40
Impact of surveillance stool culture guided selection of antibiotics in the management of pediatric small bowel transplant recipients. Pediatr Transplant (2006) 1.39
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol (2008) 1.32
Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother (2005) 1.31
Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis (2005) 1.29
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater (2009) 1.28
Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. J Gen Virol (2002) 1.27
Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol (2008) 1.26
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol (2009) 1.24
Focal adhesion kinase plays a pivotal role in herpes simplex virus entry. J Biol Chem (2005) 1.24
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther (2009) 1.24
Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl (2002) 1.23
Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells. J Virol (2006) 1.22
Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci (2008) 1.20
Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol (2007) 1.19
Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res (2010) 1.19
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res (2013) 1.12
Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther (2009) 1.12
Multiple receptor interactions trigger release of membrane and intracellular calcium stores critical for herpes simplex virus entry. Mol Biol Cell (2007) 1.10
Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother (2011) 1.10
Research gaps in defining the biological link between HIV risk and hormonal contraception. Am J Reprod Immunol (2014) 1.08
Calicivirus enteritis in an intestinal transplant recipient. Am J Transplant (2003) 1.08
Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One (2011) 1.08
Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. J Virol (2013) 1.07
NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. Antimicrob Agents Chemother (2003) 1.07
Persulfated molecular umbrellas as anti-HIV and anti-HSV agents. J Am Chem Soc (2004) 1.07
Assessment of adherence to product dosing in a pilot microbicide study. Sex Transm Dis (2007) 1.07
Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine (2011) 1.05
Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. AIDS Res Hum Retroviruses (2013) 1.04
ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. J Infect Dis (2006) 1.02
A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci (2011) 1.01
Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci (2012) 1.01
Multipurpose prevention technologies: products in development. Antiviral Res (2013) 1.00
Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract. Am J Reprod Immunol (2006) 1.00
"Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav (2014) 1.00
Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretions. PLoS One (2012) 0.99
Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS One (2012) 0.98
Changes in the soluble mucosal immune environment during genital herpes outbreaks. J Acquir Immune Defic Syndr (2012) 0.98
Association of bactericidal activity of genital tract secretions with Escherichia coli colonization in pregnancy. Am J Obstet Gynecol (2012) 0.98
Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis (2013) 0.98
HIV transmission: time for translational studies to bridge the gap. Sci Transl Med (2011) 0.97
Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci (2007) 0.97
Role of mucosal immunity in preventing genital herpes infection. Viral Immunol (2005) 0.96
Herpes simplex virus 2 (HSV-2) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy. J Virol (2012) 0.95
The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol (2005) 0.95
Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother (2005) 0.95
Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children. J Pediatr (2011) 0.94
Screening for Trichomonas vaginalis in high-risk adolescent females with a new transcription-mediated nucleic acid amplification test (NAAT): associations with ethnicity, symptoms, and prior and current STIs. J Pediatr Adolesc Gynecol (2010) 0.94
First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation. Transplantation (2006) 0.93
Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis (2012) 0.92
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob Agents Chemother (2013) 0.92
Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer. J Acquir Immune Defic Syndr (2014) 0.91
Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr (2014) 0.91
Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides. Sex Transm Dis (2009) 0.90
HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression. FASEB J (2013) 0.90
Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides. Curr Opin Infect Dis (2006) 0.90
Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures. J Acquir Immune Defic Syndr (2015) 0.89
Cervical intraepithelial neoplasia is associated with genital tract mucosal inflammation. Sex Transm Dis (2012) 0.88
Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Antivir Ther (2007) 0.88
Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women. Sex Transm Dis (2014) 0.88
Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive. PLoS One (2012) 0.87
Measuring macrodiffusion coefficients in microbicide hydrogels via postphotoactivation scanning. Biomacromolecules (2008) 0.87
Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J Control Release (2012) 0.87
Topical prophylaxis for HIV prevention in women: becoming a reality. Curr HIV/AIDS Rep (2011) 0.86
Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors. Mol Pharm (2010) 0.85